• ME Therapeutics is pursuing a NASDAQ listing, working with U.S. counsel on its draft F-1 registration statement.
• Focus has shifted to responding to the SEC’s initial round of comments, marking the next step in the listing process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ME Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260908596473) on September 08, 2026, and is solely responsible for the information contained therein.